Go to deals
TMT

Abaco3 SpA has acquired Exprivia SpA

Abaco3 SpA has acquired 43.5% of Exprivia SpA through a voluntary public tender offer.

Abaco3 SpA is a vehicle created for the purpose of tendering Exprivia SpA.

Exprivia SpA is a listed Italian company than provides consultancy, technology services and information technology solutions.

Oaklins Italy’s parent company Banca Akros acted as the appointed broker in the collection of shares in the total voluntary public tender offer of 43.5% of Exprivia SpA by Abaco3 SpA.

Parties

Talk to the deal team

Giulio Greco

Managing Director
Milan, Italy
Oaklins Italy

Marco Valsecchi

Associate
Milan, Italy
Oaklins Italy

Nicola Biancoli

Analyst
Milan, Italy
Oaklins Italy

Related deals

Amcomri Group has completed an initial public offering
Construction & Engineering Services

Amcomri Group has completed an initial public offering

Amcomri Group plc has successfully completed an initial public offering (IPO) on the AIM Market of the London Stock Exchange, successfully raising US$15 million (£12 million) through a placing. The IPO will enable Amcomri to further its ‘Buy-Improve-Build’ strategy in the UK engineering sector.

Learn more
Tekova Oyj has completed a technical listing on the Nasdaq First North Growth Market Finland
Construction & Engineering Services

Tekova Oyj has completed a technical listing on the Nasdaq First North Growth Market Finland

Tekova Oyj has successfully completed a technical listing (IPO) on the Nasdaq First North Growth Market Finland. This transaction marks a significant milestone in the company’s growth strategy, enhancing its visibility and access to capital markets.

Learn more
Bayer AG has entered into a takeover agreement with Cara Care
Healthcare | TMT

Bayer AG has entered into a takeover agreement with Cara Care

Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.

Learn more